Synuclein-One study: Skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies

Christopher H. Gibbons, Roy Freeman, Bailey Bellaire, Charles H. Adler, Dan Moore, Todd Levine

Research output: Contribution to journalArticlepeer-review


Finding an easily accessible and reliable tool to diagnose the diseases collectively defined as asynucleinopathies' is an urgent, unmet priority. The synucleinopathies include Parkinson's disease, multiple system atrophy, pure autonomic failure and dementia with Lewy bodies. There are millions of people who have a diagnosis of a synucleinopathy, with more diagnosed every year. With accessibility, ease of implementation, consistently high sensitivity (>80%) and specificity approaching 100%, skin biopsy has great potential as the clinical test of choice for the diagnosis of synucleinopathies. The large, multi-center Synuclein-One study will determine the sensitivity, specificity, accuracy and precision of α-synuclein detection within punch skin biopsies in patients with clinically established synucleinopathies using standardized, robust methods suitable for large-scale analysis. Clinical Trial Registration: NCT04700722 (

Original languageEnglish (US)
Pages (from-to)499-509
Number of pages11
JournalBiomarkers in Medicine
Issue number7
StatePublished - May 2022


  • Parkinson's disease
  • phosphorylated α-synuclein
  • skin biopsy
  • synucleinopathy

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Synuclein-One study: Skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies'. Together they form a unique fingerprint.

Cite this